Publication Cover
Amyloid
The Journal of Protein Folding Disorders
Volume 12, 2005 - Issue 2
80
Views
42
CrossRef citations to date
0
Altmetric
Original Article

Multicentre versus single centre approach to rare diseases: The model of systemic light chain amyloidosis

, , , , &
Pages 120-126 | Received 21 Jul 2003, Accepted 04 Nov 2004, Published online: 06 Jul 2009

References

  • Kyle RA, Gertz MA. Primary systemic amyloidosis: Clinical and laboratory features in 474 cases. Semin Hematol 1995;32:45–59.
  • Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ, et al. A trial of three regimens for primary amyloidosis: Colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 1997;336:1202–1207.
  • Gillmore JD, Hawkins PN, Pepys MB. Amyloidosis: A review of recent diagnostic and therapeutic developments. Br J Haematol 1997;99:245–256.
  • Falk RH, Skinner M. The systemic amyloidoses: An overview. Adv Intern Med 2000;45:107–137.
  • Merlini G. Treatment of primary amyloidosis. Semin Hematol 1995;32:60–79.
  • Dubrey SW, Cha K, Anderson J, Chamarthi B, Reisinger J, Skinner M, et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM 1998;91:141–157.
  • Gertz MA, Lacy MQ, Gastineau DA, Inwards DJ, Chen MG, Tefferi A, et al. Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL). Bone Marrow Transplant 2000;26:963–969.
  • Skinner M, Sanchorawala V, Seldin DC, Dember LM, Falk RH, Berk JL, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: An 8-year study. Ann Intern Med 2004;140:85–93.
  • Wu SS, Brady K, Anderson JJ, Vezina R, Skinner M, Neiman RS, et al. The predictive value of bone marrow morphologic characteristics and immunostaining in primary (AL) amyloidosis. Am J Clin Pathol 1991;96:95–99.
  • Perfetti V, Colli Vignarelli M, Anesi E, Garini P, Quaglini S, Ascari E, et al. The degrees of plasma cell clonality and marrow infiltration adversely influence the prognosis of AL amyloidosis patients. Haematologica 1999;84:218–221.
  • Comenzo RL, Vosburgh E, Falk RH, Sanchorawala V, Reisinger J, Dubrey S, et al. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: Survival and responses in 25 patients. Blood 1998;91:3662–3670.
  • Moreau P, Leblond V, Bourquelot P, Facon T, Huynh A, Caillot D, et al. Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: A report on 21 patients. Br J Haematol 1998;101:766–769.
  • Merlini G. Symposium on amyloid cardiomyopathy: Diagnosis and treatment, Pavia, September 21, 1996. Amyloid 1997;4:296–299.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.